期刊文献+

非ICU住院患者预防性使用注射用奥美拉唑的合理性评价 被引量:2

Rationality Evaluation of Intravenous Omeprazole Preventively Used in Non-ICU Patients
原文传递
导出
摘要 目的探讨非ICU患者预防性使用注射用奥美拉唑的合理性。方法回顾性收集宁波第二医院2014年2月出院并预防性使用注射用奥美拉唑的病历(ICU除外)中的数据,根据标准判断其合理性。结果 273份病历中使用合理的是56份(占20.5%),不合理的是217份(占79.5%),不合理的情形前3位依次是无预防用药指征、初始用药推荐选择口服剂型、疗程过长。结论医院管理部门宜建立相应标准,对临床加强教育宣导与干预,以改善注射用奥美拉唑预防性不合理使用的现状。 OBJECTIVE To discuss the rationality of intravenous omeprazole preventively used in non-ICU patients. METHODS Retrospectively collect the data from the medical record from Ningbo No.2 Hospital in February 2014 which preventively used intravenous omeprazole in non-intensive care unit and judge its rationality according to the standard. RESULTS There were 56(20.5%) reasonable cases in 273 cases of patients, while there were 217(79.5%) unreasonable cases. The unreasonable situation top three in turn were no prophylaxis indications, choice of initial drug use recommended oral dosage forms, the course was too long. CONCLUSION Currently the unreasonable situation of intravenous omeprazole preventively used is serious, the hospital management department should establish the standards, strengthen to clinical education and intervention to improve the unreasonable situation of intravenous omeprazole preventively.
出处 《中国现代应用药学》 CAS CSCD 2017年第2期281-283,共3页 Chinese Journal of Modern Applied Pharmacy
基金 宁波市自然基金项目(2015A610284) 浙江省药学会医院药学专项科研资助项目(2014ZYY34)
关键词 注射用奥美拉唑 预防应激性溃疡 非ICU住院患者 过度使用 合理性评价 intravenous omeprazole stress ulcer prophylaxis non-intensive care unit patients over-utilization rationality evaluation
  • 相关文献

参考文献5

二级参考文献40

  • 1Soumana C Nasser,Jeanette G Nassif,Hani I Dimassi.Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patients[J].World Journal of Gastroenterology,2010,16(8):982-986. 被引量:23
  • 2刘伟,戎兰.质子泵抑制剂的研究进展[J].临床内科杂志,2006,23(2):80-82. 被引量:22
  • 3于维颖,汤新强.新一代抗溃疡药质子泵抑制剂的研究[J].大连医科大学学报,2006,28(3):246-248. 被引量:19
  • 4Blum RA. Lansoprazole and omeprazole in the treatment of acid peptic disorders. Am J Health Syst Pharm ,1996, 53:1401-1415.
  • 5Barth J, Hahne W. Review article: rabeprazole-based therapy in Helicobacter pylori eradication. Aliment Pharmacol Ther, 2002, 16(Suppl 1 ) :31-33.
  • 6Nakajima N, Kuwayama H, Iwasaki A, et al. Lansoprazole reverses Helicobacter pylori-inhibited gastric epithelial cell growth. J Clin Gastroenterol, 1995, 20( Suppl 2) :S90-92.
  • 7Robinson M. Proton pump inhibitors : update on their role in acid-related gastrointestinal diseases. Int J Clin Pract, 2005, 59:709-715.
  • 8Vakil N, Lanza F, Schwartz H, et al. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther, 2004,20:99-107.
  • 9Hillman LC, Chiragakis L, Shadbolt B, et al. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust,2004,180:387-391.
  • 10Yearsley KA, Gilby LJ, Ramadas AV, et al. Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea.Aliment Pharmacol The, 2006, 24:613-619.

共引文献337

同被引文献19

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部